GA Generic Assays GmbH, established in 2002 by Professor Dr. Dirk Roggenbuck, is an independent family company that focuses primarily on products for the differential diagnosis of autoimmune diseases. Hence, GA provide solutions to the challenges faced in this diagnostic field by ensuring optimal product quality and actively engaging in the development of innovative products in new relevant areas.
In 2005, GA innovative product, Anti-Ganglioside Dot, for the diagnosis of polyneuropathy, won a technology transfer prize from the Land Brandenburg. In 2010, they were honoured by the IHK Potsdam with the Innovation Award for the identification of the main antigen Glycoprotein 2 (GP2), for the differential diagnosis of Crohn’s disease.
GA newest development is the CytoBead® Technology – a revolutionary combination of cell-based immunofluorescence, for screening, and antigen coated microparticles, for differentiation and confirmation of antibody specificity. Through this one-step method of serum testing, in comparison to the currently used two-step process, a completely new organization of the medical laboratory process is made possible.
Immunological Kits targeting the following conditions:
- Thyroid diseases
- Vasculitis/Nephritis
- Complement system
- Systemic rheumatic inflammatory diseases
- Type 1 diabetes
- Autoimmune hepatitis
- Rheumatoid arthritis
- Hemolytic-uremic syndrome
- Polyendocrinopathies
- Neuropathies
- Gastroenterology
- Anti phospholipid syndrome
- Myasthenia gravis
- Progressive systemic sclerosis
- Atypical
- Pancreatitis
- Celiac diseases
- Crohn’s diseases
